SCHEMBL864955

SCHEMBL864955

COCCN(C)c1nc2c(Cl)cccc2cc1[C@H](C)Nc1ncnc2[nH]cnc12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.46
PIK3CG P48736 3/20 0.35
GRM4 Q14833 1/20 0.35
EGFR P00533 2/20 0.34
ABCB11 O95342 1/20 0.34
TBXA2R P21731 1/20 0.34
PIK3R1 P27986 1/20 0.34
HTR2A P28223 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PDE3A Q14432 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PIK3R2 O00459 2/20 0.33
KRAS P01116 2/20 0.33
SOS1 Q07889 1/20 0.33
STK4 Q13043 1/20 0.32
STK3 Q13188 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864956 1.00 PIK3CD (0.46) PIK3CDPIK3CGGRM4EGFRABCB11
SCHEMBL863646 0.84 PIK3CD (0.50) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL863647 0.84 PIK3CD (0.50) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL864404 0.83 PIK3CD (0.48) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL864405 0.83 PIK3CD (0.48) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL863864 0.83 PIK3CD (0.45) PIK3CDPIK3CGABCB11TBXA2RPIK3R1
SCHEMBL865114 0.82 PIK3CD (0.49) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL864038 0.82 PIK3CD (0.49) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL864078 0.82 PIK3CD (0.47) PIK3CDPIK3CGEGFRABCB11TBXA2R
SCHEMBL864077 0.82 PIK3CD (0.47) PIK3CDPIK3CGEGFRABCB11TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396315-B1 QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-08-31 EP disclosed
US-8513284-B2 Fused pyridine and pyrazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2013-08-20 US disclosed
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA PIK3CD 14/4885PIK3CG 21/4885GRM4 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.